Image

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220
  • Healthcare
  • Upcoming Report
  • Mar 2022
  • Global
  • 350 Pages
  • No of Tables: 60
  • No of Figures: 220

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market, By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-Obesity), Surgery (Wedge Resection, Laparoscopic Drilling), End User (Hospital, Ambulatory Surgical Centers, Others) – Industry Trends and Forecast to 2029

Polycystic Ovarian Syndrome (PCOS) Treatment Market

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Analysis and Size

The increased prevalence of polycystic ovarian syndrome will help the polycystic ovarian syndrome (PCOS) treatment market to grow dramatically as the increased cases of polycystic ovarian syndrome, will increase the demand for the effective treatment procedure and medications, thus benefitting the market positively. According to the Centers for Disease Control and Prevention, approximately 5 million women of reproductive age have polycystic ovarian syndrome. The surge in cases will therefore directly offer opportunities for market to grow lucratively over forecast period.

  • Global Polycystic ovarian syndrome (PCOS) treatment Market was valued at USD 5481.0 million in 2021 and is expected to reach USD 8735.97 million by 2029, registering a CAGR of 6.0% during the forecast period of 2022-2029. The “laparoscopic ovarian drilling” accounts for the largest surgery segment in the polycystic ovarian syndrome (PCOS) treatment market within the forecasted period as they are the most common surgeries performed by doctors in critical conditions. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Definition

The polycystic ovarian syndrome (PCOS), is a hormonal condition that affects many women of childbearing age. Polycystic Ovary Syndrome (PCOS) is characterized by irregular or extended menstrual cycles and elevated amounts of male hormones. Although there is currently no cure for PCOS, numerous drugs are used to regulate the menstrual cycle and manage the symptoms of the condition.  It is also caused due to high levels of androgens, low-grade inflammation, cysts in the ovaries, excess insulin and genetic disorders.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Drugs (Oral Contraceptives, Antiandrogen, Insulin-Sensitizing Agents, Antidepressants, Anti-Obesity), Surgery (Wedge Resection, Laparoscopic Drilling), End User (Hospital, Ambulatory Surgical Centers, Others)

Countries Covered

U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa

Market Players Covered

Bayer AG (Germany), Allergan (Ireland), Merck & Co. (U.S.), Pfizer Inc. (U.S.), Amgen (U.S.), Agile Therapeutics (U.S.), Ferring B.V (U.S.),  Addex Therapeutics (Switzerland), Mylan N.V. (U.S.), Lupin (India), Blairex Laboratories Inc.,(U.S.), Apothecus Pharmaceutical Corp(U.S.), Eli Lilly And Company (U.S.), Novartis AG (Switzerland), BIOCAD Global (Russia), Teva Pharmaceutical Industries Ltd., (Israel) and  Johnson & Johnson Services, Inc. (U.S.)

Market Opportunities

  • Untapped potential offered by developing economies
  • Growth in awareness about polycystic ovarian syndrome treatment
  • Technological advancements in detection

Polycystic Ovarian Syndrome (PCOS) Treatment Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

Drivers

  • Growing Burden Of Polycystic Ovarian Syndrome (PCOS)

The surging cases of polycystic ovarian syndrome (PCOS), across the world is the most significant factor driving the growth for this market. Additionally, the other factors, including rising prevalence of diabetes and obesity among women, increasing hormonal disorders in women, socioeconomic factors, change in sedentary lifestyle, and growing consumption of unhealthy diet, are also expected to accelerate the market's overall growth.

Furthermore, the expanding healthcare sector, adoption of combination drugs, and rising patient adoption are also expected to fuel market growth. Moreover, the rising awareness among the patients and doctors regarding the chronic diseases and hospital-acquired infections also cushions the market’s growth within the forecasted period. The focus of leading manufacturers on expanding their geographic presence is also projected to bolster the market's growth.

Opportunities

  • Growing Investments and Advancements

Moreover, the technological advancements for detection of polycystic ovary syndrome and the growth in awareness about polycystic ovarian syndrome treatment are estimated to generate lucrative opportunities for the market. The untapped potential offered by developing economies combined with rise in adoption of polycystic ovarian syndrome treatment products will further offer numerous growth opportunities for the market.

Restraints/Challenges Global Polycystic Ovarian Syndrome (PCOS) Treatment Market

  • Side Effects Associated With Drugs

The drugs for treating polycystic ovary syndrome also have various side effects. The side effects associated with drugs such as cardiovascular risks, weight gain, abnormal glucose tolerance, increase insulin resistance and thromboembolic events are expected to obstruct market growth.

  • Stringent Drug Approval Policies

Also, the lack of approved therapeutics and lack of FDA drug approval is projected to challenge the polycystic ovarian syndrome (PCOS) treatment market in the forecast period of 2022-2029.

Furthermore, the lack of specific treatment for this disorder along with the unknown etiology and pathophysiology of polycystic ovarian syndrome will also hamper overall growth for the market.

This polycystic ovarian syndrome (PCOS) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the polycystic ovarian syndrome (PCOS) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Post Covid-19 Impact on Polycystic Ovarian Syndrome (PCOS) Treatment Market

Healthcare industry was largely impacted by the outbreak of COVID-19. The polycystic ovarian syndrome (PCOS) treatment market does not stand back as it was also adversely affected by it as pandemic had repercussions for many surgical operations, including laparoscopic ovarian drilling The imposition of the lockdown and social distancing restrictions by the government to curb the COVID-19 pandemic outbreak, led to halt of various operations, supply chain disruptions, stifling business growth, suspensions of new developments and has affected the overall treatment procedure which have impacted the market negatively. The non-essential treatment surgeries or procedures were also suspended. According to Experts at the University of Birmingham, patients who have contracted coronavirus and undertake surgery are at an increased risk of postoperative mortality, and that all non-emergent surgeries should be avoided. However, to maintain normal surgical practices, regulatory authorities established a few guidelines unique to each profession that surgeons must implement and follow to continue to offer safe and effective care to their patients throughout the COVID-19 pandemic.

On the brighter side, with the decrease in COVID-19 patients, the restrictions of the government measures are likely to relax. This will help the market witness a slight increment post COVID-19, as normal surgical practices can occur according to few guidelines that surgeons must implement and follow to continue to offer safe and effective care to their patients throughout. Healthcare practitioners have been able to restart their surgery practices as a result of the new standards. As a result, it is envisaged that laparoscopic ovarian drilling treatments will resume their usual growth post- COVID.

Recent Developments

  • In January 2020, Abbvie had a clinical trial in the works with the chemical Elagolix, which is being tested for safety and efficacy in women with polycystic ovary syndrome. The business is now conducting a Phase 2 multicenter, double-blind, randomised, placebo-controlled research to evaluate Elagolix's safety and efficacy in women with polycystic ovarian syndrome (PCOS).
  • In Jan 2020, Evotec SE and Bayer AG launched a new five-year multi-target collaboration with Celmatix Inc. to develop various clinical candidates for the treatment of polycystic ovarian syndrome, which is projected to drive the market during the forecast period.

Global Polycystic Ovarian Syndrome (PCOS) Treatment Market Scope

The polycystic ovarian syndrome (PCOS) treatment market is segmented on the basis of drugs, surgery and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs

  • Oral Contraceptives
  • Antiandrogen
  • Insulin-Sensitizing Agents
  • Antidepressants
  • Anti-Obesity

On the basis of drugs, the polycystic ovarian syndrome (PCOS) treatment market is segmented into oral contraceptives, antiandrogen, insulin-sensitizing agents, antidepressants and anti-obesity.

Surgery

  • Wedge Resection
  • Laparoscopic Drilling

On the basis of surgery, the polycystic ovarian syndrome (PCOS) treatment market is segmented into wedge resection and laparoscopic drilling. Laparoscopic ovarian drilling is expected to register a major share in the market as they are the most common surgeries performed by doctors in critical conditions.

End User

  • Hospital
  • Ambulatory Surgical Centers
  • Others

On the basis of end user, the polycystic ovarian syndrome (PCOS) treatment market is bifurcated into hospital, ambulatory surgical centers and others.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Regional Analysis/Insights

The polycystic ovarian syndrome (PCOS) treatment market is analyzed and market size insights and trends are provided by country, drugs, surgery and end user as referenced above.

The countries covered in the polycystic ovarian syndrome (PCOS) treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the polycystic ovarian syndrome (PCOS) treatment market because of the high awareness and the availability of advanced healthcare facilities within the region.

Asia-Pacific is expected to witness significant growth during the forecast period of 2022 to 2029 due to the government initiatives to raise awareness about the symptoms and diagnosis of PCOS and available treatment, which are increasing the number of women diagnosed with this syndrome within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The polycystic ovarian syndrome (PCOS) treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for polycystic ovarian syndrome (PCOS) treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the polycystic ovarian syndrome (PCOS) treatment market. The data is available for historic period 2010-2020.

Competitive Landscape and Polycystic Ovarian Syndrome (PCOS) Treatment Market Share Analysis

The polycystic ovarian syndrome (PCOS) treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to polycystic ovarian syndrome (PCOS) treatment market.

Some of the major players operating in the polycystic ovarian syndrome (PCOS) treatment market are

  • Bayer AG (Germany)
  • Allergan (Ireland)
  • Merck & Co (U.S.)
  • Pfizer Inc (U.S.)
  • Amgen (U.S.)
  • Agile Therapeutics (U.S.)
  • Ferring B.V. (U.S.)
  • Addex Therapeutics (Switzerland)
  • Mylan N.V. (U.S.)
  • Lupin (India)
  • Blairex Laboratories Inc (U.S.)
  • Apothecus Pharmaceutical Corp (U.S.)
  • Eli Lilly And Company (U.S.)
  • Novartis AG (Switzerland)
  • BIOCAD Global (Russia)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Johnson & Johnson Services, Inc (U.S.)

Research Methodology : Global Polycystic Ovarian Syndrome (PCOS) Treatment Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-polycystic-ovarian-syndrome-pcos-treatment-market


SKU-

Why Choose Us


Frequently Asked Questions

The Polycystic Ovarian Syndrome (PCOS) Treatment Market is Expected to Show a Value of USD 8735.97 million by 2029.
The Polycystic Ovarian Syndrome (PCOS) Treatment Market is Estimated to Register a CAGR of 6.0% During the Forecast Period of 2022 to 2029.
The Major Companies Operating in the Polycystic Ovarian Syndrome (PCOS) Treatment Market are Bayer AG (Germany), Allergan (Ireland), Merck & Co. (U.S.), Pfizer Inc. (U.S.), Amgen (U.S.), Agile Therapeutics (U.S.), Ferring B.V (U.S.), Addex Therapeutics (Switzerland) and Mylan N.V. (U.S.).
The Countries Covered in the Polycystic Ovarian Syndrome (PCOS) Treatment Market Report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
The Polycystic Ovarian Syndrome (PCOS) Treatment Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.